Who is sponsoring NCT04104412?

NCT04104412 is sponsored by Sclnow Biotechnology Co., Ltd..

What condition does NCT04104412 study?

NCT04104412 studies Lumbar Discogenic Pain.

What drugs are being tested in NCT04104412?

Interventions: human umbilical cord mesenchymal stem cell.

What is the status of NCT04104412?

NCT04104412 is currently RECRUITING.

Last reviewed 2025-12-04 · How we verify

The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

NCT04104412 PHASE1 RECRUITING

This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy. This experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months. The efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.

Details

Lead sponsor	Sclnow Biotechnology Co., Ltd.
Phase	PHASE1
Status	RECRUITING
Enrolment	242
Start date	Thu Aug 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Lumbar Discogenic Pain

Interventions

human umbilical cord mesenchymal stem cell

Countries

China